IP Library › Granted Patent US 9,234,040
Granted Patent B2
US 9,234,040 · App. 14/045,454 · Granted Jan 12, 2016

Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells

Inventors: Gerard Zurawski (Midlothian, TX); Jacques F. Banchereau (Montclair, NJ); Eynav Klechevsky (Haifa, IL); Sandra Zurawski (Midlothian, TX); Anne-Laure Flamar (Dallas, TX)
Assignee: Baylor Research Institute
C07K16/2851A61K39/02A61K39/12A61K39/145A61K39/21A61K47/48746A61K47/48776B82Y5/00C12N5/0639A61K2039/505A61K2039/6056C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,234,040
App. No.
14/045,454
Granted
Jan 12, 2016
Kind
B2
Abstract

The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

Claims (13)

1. A method for increasing the effectiveness of antigen presentation by a dendritic cell comprising targeting a composition comprising a Dendritic Cell Immunoreceptor (DCIR)-specific antibody or a DCIR-binding fragment thereof to the dendritic cell, wherein an antigen is attached to the antibody or the fragment thereof in the form of a fusion protein.

2. The method of claim 1 , comprising administering the fusion protein to a patient.

3. The method of claim 1 , wherein the antigen comprises a MHC epitope.

4. The method of claim 1 , wherein the fusion protein comprises multiple antigens.

5. The method of claim 1 , wherein the fusion protein comprises at least one viral antigen.

6. The method of claim 1 , wherein the fusion protein comprise a flu antigen.

7. The method of claim 1 , wherein the antigen comprises a HIV antigen.

8. The method of claim 7 , wherein the HIV antigen is from a gag, pol or env gene product.

9. The method of claim 7 , wherein the HIV antigen is from a Nef protein or reverse transcriptase.

10. The method of 1 , wherein the composition comprises an adjuvant.

11. The method of claim 10 , wherein the adjuvant is aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, MTP-PE, RIBI, DDA (dimethyldioctadecylammonium bromide), Freund's complete adjuvant, Freund's incomplete adjuvant, QuilA, a lymphokine, synthetic IFN-γ inducer, or a combination thereof.

12. The method of claim 1 , wherein the composition comprises poly I:C.

13. The method of claim 1 , wherein the antigen is a Mycobacterium tuberculosis antigen.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ADD INVENTOR ANN-LAURE FLAMAR PREVIOUSLY RECORDED ON REEL 032184 FRAME 0284. ASSIGNOR(S) HEREBY CONFIRMS THE INVENTORS EYNAV KLECHEVSKY AND SANDRA ZURAWSKI. Recorded May 5, 2014
From: KLECHEVSKY, EYNAV; ZURAWSKI, SANDRA; FLAMAR, ANNE-LAURE
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 032825/0743 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: KLECHEVSKY, EYNAV; ZURAWSKI, SANDRA
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 032184/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2014
From: ZURAWSKI, GERARD; BANCHEREAU, JACQUES F
To: BAYLOR RESEARCH INSTITUTE
Reel/Frame 032184/0300 →
Continuity (5)
Continuation 13454404 · Apr 24, 2012
Division 13234914 · Sep 16, 2011
Continuation 12024897 · Feb 1, 2008
Provisional Application 60888032 · Feb 2, 2007
Related Publication 20140134168A1 · May 15, 2014